Medicus Pharma Ltd. Common Stock Net Assets
Medicus Pharma Ltd. Common Stock net assets. Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has net assets worth $-1.22 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.11 Million) and total liabilities ($20.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Medicus Pharma Ltd. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.22 Million |
| % of Total Assets | -6.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 140.42 |
Net Assets of Medicus Pharma Ltd. Common Stock (2010–2025)
Net assets of Medicus Pharma Ltd. Common Stock from 2010 to 2025. This chart illustrates how Medicus Pharma Ltd. Common Stock's net assets have evolved over time, based on quarterly financial data. See how leveraged is Medicus Pharma Ltd. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual net assets of Medicus Pharma Ltd. Common Stock from 2010 to 2025. For live market cap and overall valuation, see market cap of Medicus Pharma Ltd. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $37.31K | -98.81% |
| 2024-12-31 | $3.13 Million | +182.04% |
| 2023-12-31 | $1.11 Million | +109.11% |
| 2022-12-31 | $-12.20 Million | -16.11% |
| 2021-12-31 | $-10.51 Million | -16668.53% |
| 2017-12-31 | $-62.65K | +96.87% |
| 2010-12-31 | $-2.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicus Pharma Ltd. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5217157100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Medicus Pharma Ltd. Common Stock Net Assets Breakdown (December 2025)
Medicus Pharma Ltd. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $57.08 Million | % |
| Other Comprehensive Income | $10.88K | % |
| Other Components | $7.19 Million | % |
| Total Equity | $-67.55K | 100.00% |
Medicus Pharma Ltd. Common Stock Competitors by Market Cap
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ECOUP OYJ EO 1
F:62H
|
$10.20 Million |
|
Pivotal Metals Ltd
AU:PVT
|
$10.20 Million |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
$10.21 Million |
|
Renew Holdings plc
LSE:RNWH
|
$10.21 Million |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
$10.20 Million |
|
Aspire BioPharma, Inc.
NASDAQ:ASBP
|
$10.20 Million |
|
Boa Concept SA
PA:ALBOA
|
$10.19 Million |
|
REC Silicon ASA
OL:RECSI
|
$10.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicus Pharma Ltd. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,134,704 to -67,554, a change of -3,202,258 (-102.2%).
- Net loss of 25,366,424 reduced equity.
- New share issuances of 18,217,431 increased equity.
- Other comprehensive income increased equity by 10,880.
- Other factors increased equity by 3,935,855.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.37 Million | -37549.85% |
| Share Issuances | $18.22 Million | +26967.21% |
| Other Comprehensive Income | $10.88K | +16.11% |
| Other Changes | $3.94 Million | +5826.24% |
| Total Change | $- | -102.16% |
Book Value vs Market Value Analysis
This analysis compares Medicus Pharma Ltd. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.31 | $2.03 | x |
| 2022-12-31 | $-1.51 | $2.03 | x |
| 2023-12-31 | $0.14 | $2.03 | x |
| 2024-12-31 | $0.27 | $2.03 | x |
| 2025-12-31 | $0.00 | $2.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicus Pharma Ltd. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-119.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -5.49% | 4.21x | 0.00x | $-493.62K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-132.63K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-472.58K |
| 2023 | -478.18% | 0.00% | 0.00x | 1.70x | $-5.43 Million |
| 2024 | -355.87% | 0.00% | 0.00x | 1.80x | $-11.47 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.36 Million |
Industry Comparison
This section compares Medicus Pharma Ltd. Common Stock's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $16,554,522,824
- Average return on equity (ROE) among peers: 23.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $-1.22 Million | 0.00% | N/A | $10.20 Million |
| AbbVie Inc (ABBV) | $5.10 Billion | 104.16% | 12.89x | $356.49 Billion |
| Amgen Inc (AMGN) | $163.50 Million | 1.04% | 0.18x | $198.99 Billion |
| Amarin Corporation PLC (AMRN) | $-129.19 Million | 0.00% | 0.00x | $252.68 Million |
| AstraZeneca PLC (AZN) | $40.87 Billion | 17.21% | 1.55x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $10.34 Billion | 11.05% | 0.92x | $246.25 Billion |
| Biogen Inc (BIIB) | $239.00 Million | 3.01% | 0.06x | $32.27 Billion |
| Bristol-Myers Squibb Company (BMY) | $10.56 Billion | 20.50% | 1.48x | $126.06 Billion |
| Gilead Sciences Inc (GILD) | $20.50 Billion | 22.57% | 2.43x | $182.40 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $1.10 Billion | 36.36% | 0.64x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $76.80 Billion | 23.36% | 1.44x | $574.95 Billion |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more